Document ID: chunk:federal_register_of_legislation:F2020C00834:reg:8:p2
Version: federal_register_of_legislation:F2020C00834
Segment Type: reg
Provision Reference: reg 8 (pt 2/4)
Character Range: 117746–121455

sensory impairments:
           (a) Bilateral blindness where:
              (i) visual acuity is less than or equal to 6/60 with corrected vision; or
              (ii) visual fields are reduced to a measured arc of less than 10 degrees;
           (b) Hearing loss ‑ a 45 decibels or greater hearing impairment in the better ear, based on a 4 frequency pure tone average (using 500, 1000, 2000 and 4000Hz);
           (c) Deaf‑blindness ‑ diagnosed by a specialist multidisciplinary team, including a professional audiological and ophthalmological evaluation.

        (12) The following dermatological conditions:
           (a) Epidermolysis Bullosa Dystrophica;
           (b) The following types of Ectodermal Dysplasias:
              (i) Hypohidrotic ectodermal dysplasia (synonym: anhidrotic ectodermal dysplasia);
              (ii) Hay Wells syndrome (synonym: ankyloblepharon, ectodermal dysplasia and clefting [AEC] syndrome);

       Note:  These are specific terms and do not apply to other ectodermal dysplasia which may have some degree of reduced sweating.
           (c) The following severe congenital ichthyoses:
              (i) Lamellar ichthyosis;
              (ii) Harlequin ichthyosis;
              (iii) Sjogren Larsson syndrome;
              (iv) Netherton syndrome;
              (v) Severe congenital ichthyosiform erythroderma;
              (vi) Generalised bullous ichthyosis (synonym: bullous ichthyosiform erythroderma, epidermolytic hyperkeratosis).

        (13) Phenylketonuria (PKU).

        (14) Other inborn errors of metabolism not specified elsewhere in this Part that are treated by medically prescribed diet to prevent neurological disability and/or severe organ damage.

        (15) Cystic Fibrosis.

        (16) Moderate to severe Osteogenesis Imperfecta with two or more fractures per year and/or significant pain that significantly limits activities of daily living.

        (17) Down syndrome.

        (18) Fragile X syndrome.

       Part 2 Medical Conditions

        (1) Chronic or end stage organ failure where the child is receiving organ specific treatment and/or awaiting transplant.

        (2) HIV/AIDS where the child is symptomatic (in addition to having lymphadenopathy) and requires treatment with a 3 or more drug antiviral regimen.

        (3) Immunodeficiency where the child requires regular immunoglobin infusions.

        (4) The following Haematological/Oncological Conditions:
           (a) Leukaemia, Haemophagocytic Lymphohistiocytosis and other childhood malignancies where the child is undergoing chemotherapy, radiotherapy or palliative care;
           (b) Haemophilia with Factor VIII or Factor IX deficiency (less than 10%);
           (c) Thalassaemia or Haemoglobinopathy requiring chelation therapy;
           (d) Chronic Transfusion Dependent Anaemia requiring chelation therapy;
           (e) Langerhan Cell Histiocytosis: disseminated (multi‑organ) disease requiring chemotherapy for longer than 6 months;
           (f) Severe congenital Neutropenia (Kostman's variant, dependent on Filgrastin).

        (5) The following Chronic Respiratory Conditions:
           (a) Chronic Respiratory Disease requiring home oxygen;
           (b) A condition where the child is dependent for his or her health on an external apparatus/machine called a ventilator to assist with breathing, either on a continuous or intermittent basis;
           (c) Long term tracheostomy where the child is cared for at home.

        (6) Severe atopic dermatitis which involves at least 75% of the body surface and which has required two or more hospitalisations of at least 5 days duration in the previous calendar year, and/or the